Should Biogen Buy Alkermes? Post author:Sam Post published:February 27, 2018 Post category:BioPharma After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making. Source: BioSpace You Might Also Like AntriaBio Announces $13 Million Close Of Private Placement Transaction And Plan To Dose First Patient With AB101 This Month July 17, 2017 31-Year-Old Biotech Guru Brings in Another $55 Million for Axovant February 2, 2017 Amgen Leaps Into the World of Regenerative Medicine With New Investment November 7, 2017
AntriaBio Announces $13 Million Close Of Private Placement Transaction And Plan To Dose First Patient With AB101 This Month July 17, 2017
